MiR-aculous New Avenues for Cancer Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 17

PMID 36248881

Authors

William W Tang

Kaylyn M Bauer

Cindy Barba

Huseyin Atakan Ekiz

Ryan M OConnell

Affiliations

Soon will be listed here.

Abstract

The rising toll of cancer globally necessitates ingenuity in early detection and therapy. In the last decade, the utilization of immune signatures and immune-based therapies has made significant progress in the clinic; however, clinical standards leave many current and future patients without options. Non-coding RNAs, specifically microRNAs, have been explored in pre-clinical contexts with tremendous success. MicroRNAs play indispensable roles in programming the interactions between immune and cancer cells, many of which are current or potential immunotherapy targets. MicroRNAs mechanistically control a network of target genes that can alter immune and cancer cell biology. These insights provide us with opportunities and tools that may complement and improve immunotherapies. In this review, we discuss immune and cancer cell-derived miRNAs that regulate cancer immunity and examine miRNAs as an integral part of cancer diagnosis, classification, and therapy.

Citing Articles

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potential.

Dong F, Zhou J, Wu Y, Gao Z, Li W, Song Z Front Cell Dev Biol. 2025; 12:1499111.

PMID: 39882259 PMC: 11774998. DOI: 10.3389/fcell.2024.1499111.

Non-Coding RNAs and Innate Immune Responses in Cancer.

Diaz C, Hernandez-Huerta M, Perez-Campos Mayoral L, Villegas M, Zenteno E, Martinez Cruz M Biomedicines. 2024; 12(9).

PMID: 39335585 PMC: 11429077. DOI: 10.3390/biomedicines12092072.

Revolutionizing cancer therapy: nanoformulation of miRNA-34 - enhancing delivery and efficacy for various cancer immunotherapies: a review.

Fawzy M, Hassan H, Sedky N, Nafie M, Youness R, Fahmy S Nanoscale Adv. 2024; .

PMID: 39309515 PMC: 11414826. DOI: 10.1039/d4na00488d.

CD28 co-stimulation: novel insights and applications in cancer immunotherapy.

Lotze M, Olejniczak S, Skokos D Nat Rev Immunol. 2024; 24(12):878-895.

PMID: 39054343 PMC: 11598642. DOI: 10.1038/s41577-024-01061-1.

Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.

Abdul Manap A, Wisham A, Wong F, Ahmad Najmi H, Ng Z, Diba R Front Cell Dev Biol. 2024; 12:1390704.

PMID: 38726321 PMC: 11079208. DOI: 10.3389/fcell.2024.1390704.

References

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Ichiyama K, Gonzalez-Martin A, Kim B, Jin H, Jin W, Xu W . The MicroRNA-183-96-182 Cluster Promotes T Helper 17 Cell Pathogenicity by Negatively Regulating Transcription Factor Foxo1 Expression. Immunity. 2016; 44(6):1284-98. PMC: 4918454. DOI: 10.1016/j.immuni.2016.05.015. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Cao L, Yang X, Chen Y, Zhang D, Jiang X, Xue P . Exosomal miR-21 regulates the TETs/PTENp1/PTEN pathway to promote hepatocellular carcinoma growth. Mol Cancer. 2019; 18(1):148. PMC: 6815431. DOI: 10.1186/s12943-019-1075-2. View

Zhu L, Tu H, Liang Y, Tang D . MiR-218 produces anti-tumor effects on cervical cancer cells in vitro. World J Surg Oncol. 2018; 16(1):204. PMC: 6186038. DOI: 10.1186/s12957-018-1506-3. View

Han M, Jung D, Morel C, Lakhani S, Kim J, Flavell R . JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science. 2012; 339(6116):218-22. PMC: 3835653. DOI: 10.1126/science.1227568. View

Swann J, Hayakawa Y, Zerafa N, Sheehan K, Scott B, Schreiber R . Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007; 178(12):7540-9. DOI: 10.4049/jimmunol.178.12.7540. View

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

10.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

11.

Pearce E, Mullen A, Martins G, Krawczyk C, Hutchins A, Zediak V . Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science. 2003; 302(5647):1041-3. DOI: 10.1126/science.1090148. View

12.

Wang X, Zhang Y, Zheng J, Yao C, Lu X . LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway. Cancer Immunol Immunother. 2021; 70(8):2235-2245. PMC: 10992874. DOI: 10.1007/s00262-020-02753-y. View

13.

Saetrom P, Heale B, Snove Jr O, Aagaard L, Alluin J, Rossi J . Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res. 2007; 35(7):2333-42. PMC: 1874663. DOI: 10.1093/nar/gkm133. View

14.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

15.

Sun W, Wang X, Li J, You C, Lu P, Feng H . MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway. Cell Death Dis. 2018; 9(4):438. PMC: 5941226. DOI: 10.1038/s41419-018-0490-4. View

16.

Weinberg R . The genetic origins of human cancer. Cancer. 1988; 61(10):1963-8. DOI: 10.1002/1097-0142(19880515)61:10<1963::aid-cncr2820611005>3.0.co;2-8. View

17.

Scherm M, Serr I, Zahm A, Schug J, Bellusci S, Manfredini R . miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes. Nat Commun. 2019; 10(1):5697. PMC: 6910913. DOI: 10.1038/s41467-019-13587-3. View

18.

Ji Y, Wrzesinski C, Yu Z, Hu J, Gautam S, Hawk N . miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc Natl Acad Sci U S A. 2014; 112(2):476-81. PMC: 4299215. DOI: 10.1073/pnas.1422916112. View

19.

Dudley M, Wunderlich J, Yang J, Sherry R, Topalian S, Restifo N . Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005; 23(10):2346-57. PMC: 1475951. DOI: 10.1200/JCO.2005.00.240. View

20.

Boutilier A, Elsawa S . Macrophage Polarization States in the Tumor Microenvironment. Int J Mol Sci. 2021; 22(13). PMC: 8268869. DOI: 10.3390/ijms22136995. View